$49.78 +0.90 (%) Prothena Corporation PLC - NASDAQ

Jan. 20, 2017 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Prothena Grabbing At Chunk Of $19B Immunotherapy Market: CEO Exclusive

    Investors Business Daily | Jan. 20, 2017 | 16:27PM EST
  2. Drug Stocks Topple On Donald Trump's Pledge To Bring Down Drug Prices

    Investors Business Daily | Dec. 7, 2016 | 11:36AM EST
  3. Drug Stocks Topple On Donald Trump's Pledge To Bring Down Drug Prices

    Investors Business Daily | Dec. 7, 2016 | 11:36AM EST
  4. Battleground: Alnylam Plunges After Revusiran Pulled, But Some See Opportunity

    TalkMarkets | Oct. 6, 2016 | 19:50PM EST
  5. The Best-Performing Non-S&P Stocks of 2015

    GuruFocus | Dec. 30, 2015 | 16:01PM EST
  6. Top-Performing Non-S&P 500 Stocks of the Year

    GuruFocus | Dec. 30, 2015 | 16:01PM EST
  7. Top Stocks 2015: Biotechs, Wayfair, Netflix, Amazon

    IBD | Dec. 30, 2015 | 08:02AM EST
  8. The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings

    GuruFocus | Nov. 4, 2015 | 15:42PM EST
  9. Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson's Disease and Movement Disorders

    Benzinga | Jun. 8, 2015 | 15:05PM EST
  10. Benzinga's Top Initiations

    Benzinga | Jun. 1, 2015 | 09:17AM EST
  11. UBS Initiates Prothena Corporation At Buy

    Benzinga | Jun. 1, 2015 | 07:19AM EST
  12. Prothena Announces Presentation of Clinical Data From the Ongoing Phase 1/2 NEOD001 Study and Systemic Amyloidosis Patient Survey Results

    Benzinga | May. 21, 2015 | 07:03AM EST
  13. UPDATE: Prothena Receives FDA Fast Track Designation for NEOD001

    Benzinga | Dec. 15, 2014 | 16:07PM EST
  14. Prothena Reports Initiation of NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study

    Benzinga | Dec. 2, 2014 | 16:06PM EST
  15. Benzinga's Top Initiations

    Benzinga | Jul. 11, 2014 | 08:18AM EST
  16. Oppenheimer Initiates Prothena With Outperform

    Benzinga | Jul. 11, 2014 | 07:48AM EST
  17. Morning Market Losers

    Benzinga | Jun. 25, 2014 | 08:49AM EST
  18. Eight Companies Announce Offerings After The Close Monday: PRTA, AMSG, BRX, DSGX, GIII, KNOP, FANG, TSLX

    Benzinga | Jun. 23, 2014 | 17:53PM EST
  19. Mid-Afternoon Market Update: Markets Show Strength as Prothena Shares Plummet

    Benzinga | Apr. 29, 2014 | 14:45PM EST
  20. Mid-Afternoon Market Update: Markets Post a Large Rally as Intuitive Surgical Shares Remain Down

    Benzinga | Apr. 9, 2014 | 14:54PM EST
  21. Mid-Day Market Update: Alcoa Surges On Upbeat Earnings; Intuitive Surgical Shares Slip

    Benzinga | Apr. 9, 2014 | 12:06PM EST
  22. Mid-Morning Market Update: Markets Open Higher; Constellation Brands Profit Beats Street View

    Benzinga | Apr. 9, 2014 | 09:23AM EST
  23. Morning Market Movers

    Benzinga | Apr. 9, 2014 | 08:39AM EST
  24. First Human Dosed in Phase 1 Study of PRX002 for Treatment of Parkinson's Disease

    Benzinga | Apr. 8, 2014 | 15:09PM EST
  25. Mid-Afternoon Market Update: Markets Drop Sharply During Janet Yellen's First Conference

    Benzinga | Mar. 19, 2014 | 15:19PM EST
  26. Afternoon Movers for Wednesday, March 19th 2014

    Benzinga | Mar. 19, 2014 | 14:54PM EST
  27. Mid-Day Market Update: Oracle Shares Decline On Weak Results; Horizon Pharma Jumps

    Benzinga | Mar. 19, 2014 | 11:04AM EST
  28. Mid-Morning Market Update: Markets Edge Higher; FedEx Profit Misses Estimates

    Benzinga | Mar. 19, 2014 | 09:12AM EST
  29. Stocks Hitting 52-Week Highs

    Benzinga | Mar. 19, 2014 | 09:12AM EST
  30. Morning Market Movers

    Benzinga | Mar. 19, 2014 | 08:36AM EST
  31. Prothena Announces Appointment of Chief Business Officer

    Benzinga | Mar. 3, 2014 | 16:07PM EST
  32. Prothena Announces Pricing of Secondary 2.67M Share Offering of Ordinary Shares by Perrigo at $26.00

    Benzinga | Jan. 29, 2014 | 08:02AM EST
  33. Prothena Announces Proposed Secondary Offering of 2.767M Ordinary Shares by Perrigo

    Benzinga | Jan. 27, 2014 | 16:16PM EST
  34. Mid-Day Market Update: Ciena Drops On Downbeat Profit; Facebook Shares Spike Higher

    Benzinga | Dec. 12, 2013 | 12:33PM EST
  35. Mid-Morning Market Update: Markets Mostly Lower; Lululemon Issues Downbeat Guidance

    Benzinga | Dec. 12, 2013 | 10:55AM EST
  36. UPDATE: Credit Suisse Raises PT on Prothena Following Deal with Roche

    Benzinga | Dec. 12, 2013 | 10:31AM EST
  37. Stocks Hitting 52-Week Highs

    Benzinga | Dec. 12, 2013 | 10:24AM EST
  38. Benzinga's Top #PreMarket Gainers

    Benzinga | Dec. 12, 2013 | 08:09AM EST
  39. Roche, Prothena Enter Into Worldwide Collaboration to Co-Develop Antibodies for Treatment of Parkinson's Disease

    Benzinga | Dec. 11, 2013 | 16:07PM EST
  40. Benzinga's Top Initiations

    Benzinga | Nov. 15, 2013 | 08:30AM EST
  41. UPDATE: Bank of America Merrill Lynch Initiates On Prothena On Possible Benefits of D001

    Benzinga | Nov. 15, 2013 | 08:11AM EST
  42. Benzinga's Volume Movers

    Benzinga | Oct. 3, 2013 | 09:45AM EST
  43. US Stock Futures Down Ahead Of Jobless Claims Data

    Benzinga | Oct. 3, 2013 | 06:05AM EST
  44. Prothena Prices 5.91M Share Offering at $22.00/Share

    Benzinga | Oct. 3, 2013 | 05:14AM EST
  45. Wedbush Reiterates Outperform on Prothena Following Management Access Conference

    Benzinga | Aug. 20, 2013 | 11:35AM EST
  46. Stocks Hitting 52-Week Lows

    Benzinga | Jan. 8, 2013 | 03:27AM EST
  47. Stocks Hitting 52-Week Lows

    Benzinga | Jan. 4, 2013 | 03:44AM EST
Trading Center